Literature DB >> 15274698

Controversies in perioperative management of blood thinners in dermatologic surgery: continue or discontinue?

Joseph Alcalay1, Ronen Alkalay.   

Abstract

BACKGROUND: The use of blood thinners has increased dramatically in recent years among the general, and especially among the elderly, population. When these patients need to undergo cutaneous surgery, the surgeon encounters the obvious problem of whether to stop these medications before surgery.
OBJECTIVE: The objective was to evaluate the risks and benefits associated with the continuation of blood thinners perioperatively in cutaneous and Mohs micrographic surgery.
METHODS: The study comprises two parts: a search of the literature in English that examined articles that related to the perioperative use of blood thinners in dermatologic surgery and a presentation of data of continuous warfarin therapy in patients who underwent Mohs surgery in our practice.
RESULTS: A total of 15 articles were published in the literature until October 2003. One article showed an increase in complications in patients treated with warfarin, but not with aspirin. All other articles showed no increase in complications during the perioperative period. Data from our practice showed that of a total of 2790 patients, 68 were operated on while taking warfarin (2.4%). Intraoperative bleeding was easily controlled and postoperative bleeding was not recorded in any of the patients.
CONCLUSION: Continuous treatment with blood thinners perioperatively in patients undergoing Mohs and cutaneous surgery is not associated with an increase in surgical complications. Discontinuation of these medications may increase the risk of cerebral and cardiovascular complications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15274698     DOI: 10.1111/j.1524-4725.2004.30333.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  8 in total

1.  [Management of fatal postoperative hemorrhage after subtotal thyroidectomy. Individual error or structural deficit--a suitable case for discussion of the multi-specialty on-call team service? Critical comment on the decision by the Augsburg District Court].

Authors:  H Dralle
Journal:  Chirurg       Date:  2006-05       Impact factor: 0.955

Review 2.  Needs assessment for Mohs micrographic surgery.

Authors:  Maryam M Asgari; Jonathan M Olson; Murad Alam
Journal:  Dermatol Clin       Date:  2012-01       Impact factor: 3.478

Review 3.  [Ambulatory dermatologic surgery].

Authors:  T Dirschka; N von Schroeders; M Heiss; W Büchel
Journal:  Hautarzt       Date:  2005-05       Impact factor: 0.751

4.  The oncology treatment of patients who use oral anticoagulants is connected with high risk of bleeding complications.

Authors:  Zeljko Kovac; Mirjana Kovac; Gorana Mitic; Nebojsa Antonijevic
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

5.  Documentation of various approaches and outcomes in patients on warfarin undergoing dental procedures: a review article.

Authors:  Fayez El Shaer; Ismael Raslan; Nora Al Osaimi; Ghada Bawazeer; Fhakr Alayobi; Tarek Alhogbani; Suliman Kharabsheh; Walid Al Habeeb
Journal:  Am J Cardiovasc Dis       Date:  2016-09-15

Review 6.  Management of keratinocyte carcinoma - Special considerations in the elderly.

Authors:  Alison Bailey; Brooke Vasicek; Joy Tao; Monica Janeczek; Andia Mitri; Rebecca Tung
Journal:  Int J Womens Dermatol       Date:  2019-05-18

Review 7.  Perioperative Considerations for Antithrombotic Therapy in Oculofacial Surgery: A Review of Current Evidence and Practice Guidelines.

Authors:  Christian Kim; Margaret L Pfeiffer; Jessica R Chang; Michael A Burnstine
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2022-01-11       Impact factor: 2.011

8.  Aspirin use and bleeding volume in skin cancer patients undergoing surgery: a randomized controlled trial.

Authors:  Arman Engheta; Shahryar Hadadi Abianeh; Ali Atri; Mehdi Sanatkarfar
Journal:  Daru       Date:  2016-07-28       Impact factor: 3.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.